6533b829fe1ef96bd128ad1a

RESEARCH PRODUCT

Myeloid cell heterogeneity in lung cancer: implication for immunotherapy

Mario P. ColomboMarina Chiara GarassinoSabina SangalettiClaudio TripodoRoberto Ferrara

subject

Cancer ResearchLung NeoplasmsMyeloidmedicine.medical_treatmentImmunologyCellGene ExpressionContext (language use)ReviewSettore MED/08 - Anatomia PatologicaBiologyMetastasis03 medical and health sciences0302 clinical medicineImmune systemBiomarkers TumormedicineAnimalsHumansImmunology and AllergyMolecular Targeted TherapyDNA-based trapsLung cancerLung cancer · Myeloid cells · DNA-based traps · ImmunotherapyLungDisease ManagementImmunotherapymedicine.diseaseImmunohistochemistrymedicine.anatomical_structureOncologyMyeloid cellsCancer researchDisease SusceptibilityImmunotherapyLung cancerBiomarkers030215 immunology

description

Lung is a specialized tissue where metastases from primary lung tumors takeoff and those originating from extra-pulmonary sites land. One commonality characterizing these processes is the supportive role exerted by myeloid cells, particularly neutrophils, whose recruitment is facilitated in this tissue microenvironment. Indeed, neutrophils have important part in the pathophysiology of this organ and the key mechanisms regulating neutrophil expansion and recruitment during infection can be co-opted by tumor cells to promote growth and metastasis. Although neutrophils dominate the myeloid landscape of lung cancer other populations including macrophages, dendritic cells, mast cells, basophils and eosinophils contribute to the complexity of lung cancer TME. In this review, we discuss the origin and significance of myeloid cells heterogeneity in lung cancer, which translates not only in a different frequency of immune populations but it encompasses state of activation, morphology, localization and mutual interactions. The relevance of such heterogeneity is considered in the context of tumor growth and response to immunotherapy.

https://doi.org/10.1007/s00262-021-02916-5